Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Evenity is a prescription sclerostin inhibitor containing romosozumab-aqqg. It treats osteoporosis in postmenopausal women at high risk for fracture, including women with prior osteoporotic fracture, multiple fracture risk factors, or inadequate response or intolerance to other osteoporosis therapy. Treatment is limited to 12 monthly doses.
read more about evenity ...Romosozumab inhibits sclerostin, a regulatory protein involved in bone metabolism. Blocking sclerostin increases bone formation and, to a lesser degree, decreases bone resorption. These effects increase bone mass and improve bone strength during the treatment period.
Evenity is used for postmenopausal women with osteoporosis who have a high fracture risk or who have failed or cannot tolerate other osteoporosis therapy. Low blood calcium is corrected before treatment. Calcium and vitamin D intake are maintained during therapy.
The recommended dose is 210 mg by subcutaneous injection once every month for 12 doses. A full dose requires two consecutive 105 mg injections given by a healthcare professional in the abdomen, thigh, or upper arm. Treatment beyond 12 monthly doses is not recommended under current labeling.
Evenity carries a boxed warning for possible myocardial infarction, stroke, and cardiovascular death. Treatment does not start in patients who had a myocardial infarction or stroke within the previous year. Other concerns include hypersensitivity, hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures.
Evenity treats osteoporosis in postmenopausal women at high risk for fracture.
Evenity is given once monthly as two consecutive injections for a total dose of 210 mg.
Current labeling limits treatment to 12 monthly doses.
Yes. The boxed warning concerns possible myocardial infarction, stroke, and cardiovascular death.
DailyMed - EVENITY (romosozumab-aqqg) injection, solution. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=471baba2-7154-4488-9891-0db2f46791e7. Date Accessed September 30, 2026.
EVENITY (romosozumab-aqqg) Prescribing Information. Amgen. https://www.pi.amgen.com/united_states/evenity/evenity_pi.pdf. Date Accessed September 30, 2026.
NDA/BLA Multi-disciplinary Review and Evaluation - EVENITY (romosozumab). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761062Orig1s000MultidisciplineR.pdf. Date Accessed September 30, 2026.
Romosozumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Romosozumab. Date Accessed September 30, 2026.
Romosozumab-aqqg Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619026.html. Date Accessed September 30, 2026.